Published in Neurology on August 30, 2013
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2014) 1.29
AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm (2014) 1.17
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One (2013) 0.94
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol (2014) 0.94
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol (2014) 0.88
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurol (2014) 0.83
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology (2015) 0.81
AQP4 antibody serostatus: Is its luster being lost in the management and pathogenesis of NMO? Neurology (2013) 0.79
Neuromyelitis optica spectrum disorders: An update. Ann Indian Acad Neurol (2015) 0.77
Tuberculous nephritis accompanying neuromyelitis optica: causal or coincidental association? J Neurol (2014) 0.76
CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol (2014) 0.76
Neuroimmunology: Aquaporin-4-antibody-seronegative neuromyelitis optica is less common than previously thought. Nat Rev Neurol (2013) 0.75
Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination. Case Rep Neurol (2015) 0.75
Protective environmental factors for neuromyelitis optica. Neurology (2014) 0.75
Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. AJNR Am J Neuroradiol (2017) 0.75
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol (2016) 0.75
Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD). PLoS One (2016) 0.75
Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. PLoS One (2016) 0.75
Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75
Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord (2017) 0.75
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology (2012) 3.79
Neuromyelitis optica. J Neuroophthalmol (2012) 3.29
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology (2010) 1.75
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol (2008) 1.51
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol (2010) 1.20
Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08
Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Mult Scler (2009) 1.05
The role of aquaporin-4 antibodies in Chinese patients with neuromyelitis optica. J Clin Neurosci (2012) 0.98
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
A genome-wide association study of red blood cell traits using the electronic medical record. PLoS One (2010) 2.59
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02
Do not treat from CIS onset: evaluate disease course and prognosis first--yes. Mult Scler (2012) 2.01
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93
Re-evaluation of the diagnostic criteria for Wilson disease in children with mild liver disease. Hepatology (2010) 1.87
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Demyelination versus remyelination in progressive multiple sclerosis. Brain (2010) 1.82
An approach to the diagnosis of acute transverse myelitis. Semin Neurol (2008) 1.80
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79